Ulcerative Colitis Video Perspectives

Dubinsky reports receiving consulting fees from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech, Gilead, Janssen, Pfizer, Prometheus Biosciences, Roche, Takeda and UCB; participating in contracted research for AbbVie, Janssen, Pfizer and Prometheus Biosciences; holding ownership interest/stock in Trellus Health; and receiving licensing fees from Takeda.

February 01, 2023

2 min watch

Save

VIDEO: How COVID-19 has impacted ulcerative colitis care

Transcript

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

So Covid has been interesting. I mean, wow. I remember on March 17th, that first Friday having an international organization of IBD as society that many of us belong to, sort of thinking what do we do with our medications? I mean we had Italy on the phone because they were one of the first to have like Remicade use in IBD patients.

You know, we were trying to figure out because it was in Italy, for example, first before and learning from what is happening around the world. Our friends from Hong Kong were on the call. I mean, it was like, it was crazy. And I remember us all thinking like, okay folks we need to focus. What do we do with our medication? Are they unsafe? Should we be stopping? Should we be treating?

And then we, and you know, we sort of put out a guideline that we weren't a hundred percent sure we had enough data, but we were pretty right on what our guidance was. So I think when you have a collective global community working together, specifically for IBD patients, amazing things happen. And then we had a consensus on vaccines and we were pretty close on what we said for vaccines as well. So I was really proud of the international community.

And we had the secure registry which was an amazing registry out of Mount Sinai and UNC, Michael Kappelman and Eric Brenner all that group out there putting out this incredible data registry to collect information. It was like an incredible movement. I felt like Covid brought a lot of us together and it was like, you know, for many reasons.

But really from the scientific advancement we were all aware of what the science advancements were. But when it came to IBD, we learned a lot. So we were very clear that we learned our meds were actually helpful. They were not harmful unless you were on steroids or you had ongoing disease activity which goes to the pregnancy question that we talked about that good disease control will change the overall health whether it's Covid or some other sort of adversity or health, you know, health barrier that our patients have to go through.